Beigene, Ltd. (NASDAQ:ONC) Insider Sells $1,286,150.00 in Stock

Beigene, Ltd. (NASDAQ:ONC) insider Lai Wang sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $257.23, for a total transaction of $1,286,150.00. Following the completion of the sale, the insider now owns 920,920 shares in the company, valued at $236,888,251.60. This represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Beigene Stock Up 7.5 %

Beigene stock opened at $278.38 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $287.88. The firm has a market capitalization of $27.24 billion, a PE ratio of -33.78, a PEG ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last announced its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. On average, sell-side analysts expect that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.